| Public | OMER |
| Date | 10/09 |
| Post IPO Valuation | $68.2M |
| Website | omeros.com |
| Category | BioTech |
| Employees | |
| Description | Clinical Stage Bio |
| TOTAL | $63M |
| VENTURE FUNDING TOTAL | $63M |
| Series E, 2/07 Aravis Ventures ARCH Venture Partners The Grosvenor Funds Novartis Venture Fund Southern Cross Venture Partners Stanley Medical Research Institute Trevi Health Ventures WRF Capital | $63M |
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.
